Influence of ligand binding kinetics on functional inhibition of human recombinant serotonin and norepinephrine transporters (Q39758568)

14 September 2017

title

Influence of ligand binding kinetics on functional inhibition of human recombinant serotonin and norepinephrine transporters (English)

1 reference

14 September 2017

0 references

0 references

1 reference

William J Martin

3

0 references

author name string

Pamela R Tsuruda

1

1 reference

14 September 2017

Joey Yung

2

1 reference

14 September 2017

Ray Chang

4

1 reference

14 September 2017

Ngoc Mai

5

1 reference

14 September 2017

Jacqueline A M Smith

6

1 reference

14 September 2017

publication date

28 December 2009

1 reference

Journal of Pharmacological and Toxicological Methods

14 September 2017

published in

1 reference

14 September 2017

volume

61

1 reference

14 September 2017

issue

2

1 reference

14 September 2017

page(s)

192-204

1 reference

A new look at the statistical model identification

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Antidepressants targeting the serotonin reuptake transporter act via a competitive mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

The binding sites for cocaine and dopamine in the dopamine transporter overlap

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Binding characteristics of selective serotonin reuptake inhibitors with relation to emission tomography studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Validation of a fluorescence-based high-throughput assay for the measurement of neurotransmitter transporter uptake activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Kinetic and thermodynamic assessment of binding of serotonin transporter inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Studies of the biogenic amine transporters. XI. Identification of a 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909) analog that allosterically modulates the serotonin transporter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

The kinetics of action of acetylcholine antagonists in smooth muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Antidepressant binding site in a bacterial homologue of neurotransmitter transporters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Fluoxetine (Prozac) binding to serotonin transporter is modulated by chloride and conformational changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Plasma membrane monoamine transporters: structure, regulation and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.12.003

10.1016/J.VASCN.2009.12.003

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference